Market revenue in 2023 | USD 3,453.9 million |
Market revenue in 2030 | USD 7,915.1 million |
Growth rate | 12.6% (CAGR from 2023 to 2030) |
Largest segment | Metabolic disorders |
Fastest growing segment | Metabolic disorders |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cancer, Metabolic disorders, Cardiovascular disorders, Respiratory disorders, Gastrointestinal disorders, Infectious disease, Pain, Dermatological disorders, Neurological disorders, Renal disorders |
Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Amgen Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, Sanofi SA, Roche Holding AG, Novartis AG ADR, Novo Nordisk A/S ADR, GlaxoSmithKline, Ironwood Pharmaceuticals Inc Class A, Ipsen SA, Radius Health |
Metabolic disorders was the largest segment with a revenue share of 59.4% in 2023. Horizon Databook has segmented the Latin America peptide therapeutics market based on cancer, metabolic disorders, cardiovascular disorders, respiratory disorders, gastrointestinal disorders, infectious disease, pain, dermatological disorders, neurological disorders, renal disorders covering the revenue growth of each sub-segment from 2018 to 2030.
The Latin America market for peptide therapeutics has seen considerable growth, driven by a high prevalence of diseases and a surge in the demand for peptide-based medications. Countries such as Brazil and Argentina stand out as significant hubs for these drugs within the region.
Government support and collaborative research endeavors are expected to play crucial roles in fostering market development. In addition, the rising need for peptide-based drugs, influenced by the current disease landscape & strong interest from healthcare professionals, is a significant factor in market expansion.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account